Procyon Advisors’s Titan Pharmaceuticals TTNP Stock Holding History

Procyon Advisors’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-8	Closed	-$2K	–	989
2020 Q2	$2K	Buy	+8	New	+$1.38K	﹤0.01%	947

Other funds holding TTNP

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CWM

Cornerstone Wealth Management St. Peters, Missouri $2B AUM 19.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Procyon Advisors's TTNP Position: Q3 2020 in Review

Procyon Advisors sold out of Titan Pharmaceuticals (TTNP) in Q3 2020, closing a stake of 8 shares — an estimated $2K sold.

Procyon Advisors first reported a position in TTNP in Q2 2020 and held it in 1 quarter. The position peaked at $2K in Q2 2020. 16 funds tracked by Wall St. Rank hold TTNP as of Q3 2020.

Procyon Advisors reported no remaining Titan Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Procyon Advisors sold 8 Titan Pharmaceuticals shares in Q3 2020, an estimated $2K.
Procyon Advisors first reported a position in Titan Pharmaceuticals in Q2 2020 and held it in 1 quarter.
Procyon Advisors's Titan Pharmaceuticals position peaked at $2K in Q2 2020.
16 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2020.

Based on Procyon Advisors's 13F filing for Q3 2020, filed 22 Oct 2020.